Nina Zhou, BA, Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Sara Bilimoria, BA, Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Peter A. Lio, MD, Northwestern University Feinberg School of Medicine, and Medical Dermatology Associates of Chicago, Chicago, IL.

Dr. Lio reports research grants/funding from the National Eczema Association, Regeneron/Sanofi Genzyme, and AbbVie; is on the speaker's bureau for Regeneron/Sanofi Genzyme, Pfizer, Galderma, and L'Oreal; reports being a part of the consulting/advisory boards for Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Eli Lilly, Micreos (stock options), La Roche Posay/L'Oreal, Pierre-Fabre, Johnson & Johnson, Unilever, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs (stock options), Galderma, Arbonne, Amyris, Bodewell, YobeeCare (stock options), and Burt's Bees. In addition, Dr. Lio has a patent pending for a Theraplex product with royalties paid and is a board member and scientific advisory committee member of the National Eczema Association. The other authors report no conflicts of interest.

Correspondence concerning this article should be addressed to Peter A. Lio, MD, Northwestern University Feinberg School of Medicine, Medical Dermatology Associates, 363 W. Erie Street, Suite 350, Chicago, IL 60654. E-mail: pete[email protected]